RECRUITING

Effect of MitoQ on Platelet Function and Reactive Oxygen Species Generation in Patients With Sickle Cell Anemia

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

MitoQ is commercially available as a dietary supplement and it has been tested as a potential drug in other diseases, but it has never been tested in patients with sickle cell disease. The goal of this research is to study if MitoQ, a molecule that works as an antioxidant by removing potentially damaging agents in a living organism, improves platelet function in patients with sickle cell disease (SCD).

Official Title

Effect of MitoQ on Platelet Function and Reactive Oxygen Species (ROS) Generation in Patients With Sickle Cell Anemia

Quick Facts

Study Start:2020-03-01
Study Completion:2026-06-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04109820

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * African American
  2. * Patients with sickle cell anemia
  3. * 18 years old or older
  4. * African American healthy controls
  5. * 18 years of age or older
  1. 1. Pregnancy,
  2. 2. Known hypertension,
  3. 3. Hemodialysis and active obstructive sleep apnea requiring treatment.
  4. 4. Use of anti-platelet medication or have had transfusion in the 4 weeks prior to enrollment.

Contacts and Locations

Study Contact

Mikhil N Bamne, PhD
CONTACT
(412) 648-6920
bamnemn2@upmc.edu
Jude Jonassaint, RN
CONTACT
412-692-2086
jonassaintjc@upmc.edu

Principal Investigator

Ramasubramanian Kalpatthi, MD
PRINCIPAL_INVESTIGATOR
University of Pittsburgh

Study Locations (Sites)

Magee Women's Hospital
Pittsburgh, Pennsylvania, 15213
United States
UPMC Montefiore
Pittsburgh, Pennsylvania, 15213
United States
UPMC Presbyterian
Pittsburgh, Pennsylvania, 15213
United States
Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, 15224
United States
Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232
United States

Collaborators and Investigators

Sponsor: University of Pittsburgh

  • Ramasubramanian Kalpatthi, MD, PRINCIPAL_INVESTIGATOR, University of Pittsburgh

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2020-03-01
Study Completion Date2026-06-30

Study Record Updates

Study Start Date2020-03-01
Study Completion Date2026-06-30

Terms related to this study

Keywords Provided by Researchers

  • Basal platelet activation
  • MitoQ
  • mitochondrial ROS (Reactive Oxygen Species)

Additional Relevant MeSH Terms

  • Sickle Cell Disease